CytoDyn (OTC: CYDY) Submits 510(k) Pre-Submission Application to U.S. FDA for ProstaGene(TM) Prognostic Test
Dr. Richard Pestell, who leads CytoDyn’s cancer, NASH and GvHD programs, recently named to The Order of Australia, established by Queen Elizabeth II VANCOUVER, Washington, June 19, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the […]
